Flavopiridol HCl (BioDeep_00000015380)
代谢物信息卡片
Flavopiridol hydrochloride
化学式: C21H21Cl2NO5 (437.07967160000004)
中文名称: 夫拉平度盐酸盐
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O.Cl
InChI: /m0./s1
描述信息
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
D006133 - Growth Substances > D006131 - Growth Inhibitors
D000970 - Antineoplastic Agents
同义名列表
2 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:90998
- KEGG: C72284
- KEGGdrug: D02880
- PubChem: 9910986
- ChEMBL: CHEMBL2105698
- CAS: 131740-09-5
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Hemant Joshi, Hardeep Singh Tuli, Anuj Ranjan, Abhishek Chauhan, Shafiul Haque, Seema Ramniwas, Gurpreet Kaur Bhatia, Divya Kandari. The Pharmacological Implications of Flavopiridol: An Updated Overview.
Molecules (Basel, Switzerland).
2023 Nov; 28(22):. doi:
10.3390/molecules28227530. [PMID: 38005250] - Jiajia Mou, Shuang Qiu, Danghui Chen, Yanru Deng, Teka Tekleab. Design, synthesis, and primary activity assays of baicalein derivatives as cyclin-dependent kinase 1 inhibitors.
Chemical biology & drug design.
2021 10; 98(4):639-654. doi:
10.1111/cbdd.13917. [PMID: 34233076] - Yongzhan Sun, Zhiheng Liu, Xinyi Cao, Yi Lu, Zeyun Mi, Chaoran He, Jing Liu, Zhanye Zheng, Mulin Jun Li, Tiegang Li, Dechao Xu, Ming Wu, Ying Cao, Yuhao Li, Baoxue Yang, Changlin Mei, Lirong Zhang, Yupeng Chen. Activation of P-TEFb by cAMP-PKA signaling in autosomal dominant polycystic kidney disease.
Science advances.
2019 06; 5(6):eaaw3593. doi:
10.1126/sciadv.aaw3593. [PMID: 31183407] - Sandip B Bharate, Vikas Kumar, Shreyans K Jain, Mubashir J Mintoo, Santosh K Guru, Vijay K Nuthakki, Mohit Sharma, Sonali S Bharate, Sumit G Gandhi, Dilip M Mondhe, Shashi Bhushan, Ram A Vishwakarma. Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor.
Journal of medicinal chemistry.
2018 02; 61(4):1664-1687. doi:
10.1021/acs.jmedchem.7b01765. [PMID: 29370702] - Carl LaCerte, Vijay Ivaturi, Joga Gobburu, Jacqueline M Greer, L Austin Doyle, John J Wright, Judith E Karp, Michelle A Rudek. Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017 Jul; 23(14):3592-3600. doi:
10.1158/1078-0432.ccr-16-2629. [PMID: 28174232] - Bhumika Ray, Shweta Agarwal, Neelam Lohani, Moganty R Rajeswari, Ranjana Mehrotra. Structural, conformational and thermodynamic aspects of groove-directed-intercalation of flavopiridol into DNA.
Journal of biomolecular structure & dynamics.
2016 Nov; 34(11):2518-35. doi:
10.1080/07391102.2015.1118708. [PMID: 26599132] - Peter H Wiernik. Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia.
Expert opinion on investigational drugs.
2016 Jun; 25(6):729-34. doi:
10.1517/13543784.2016.1169273. [PMID: 26998706] - Yeming Han, Shanshan Zhao, Yaoqin Gong, Guihua Hou, Xi Li, Li Li. Serum cyclin-dependent kinase 9 is a potential biomarker of atherosclerotic inflammation.
Oncotarget.
2016 Jan; 7(2):1854-62. doi:
10.18632/oncotarget.6443. [PMID: 26636538] - Yu B Y Sun, Xinli Qu, Victor Howard, Lie Dai, Xiaoyun Jiang, Yi Ren, Ping Fu, Victor G Puelles, David J Nikolic-Paterson, Georgina Caruana, John F Bertram, Mark W Sleeman, Jinhua Li. Smad3 deficiency protects mice from obesity-induced podocyte injury that precedes insulin resistance.
Kidney international.
2015 Aug; 88(2):286-98. doi:
10.1038/ki.2015.121. [PMID: 25945408] - Daniela Cihalova, Frantisek Staud, Martina Ceckova. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.
Cancer chemotherapy and pharmacology.
2015 Jul; 76(1):105-16. doi:
10.1007/s00280-015-2772-1. [PMID: 25986678] - N Nagasundaram, C George Priya Doss. Predicting the impact of single-nucleotide polymorphisms in CDK2-flavopiridol complex by molecular dynamics analysis.
Cell biochemistry and biophysics.
2013 Jul; 66(3):681-95. doi:
10.1007/s12013-012-9512-5. [PMID: 23300027] - Beata Holkova, Jeffrey G Supko, Matthew M Ames, Joel M Reid, Geoffrey I Shapiro, Edward Brent Perkins, Viswanathan Ramakrishnan, Mary Beth Tombes, Connie Honeycutt, Renee M McGovern, Maciej Kmieciak, Ellen Shrader, Martha D Wellons, Heidi Sankala, Austin Doyle, John Wright, John D Roberts, Steven Grant. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013 Apr; 19(7):1873-83. doi:
10.1158/1078-0432.ccr-12-2926. [PMID: 23515411] - Jia Ji, Diane R Mould, Kristie A Blum, Amy S Ruppert, Ming Poi, Yuan Zhao, Amy J Johnson, John C Byrd, Michael R Grever, Mitch A Phelps. A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2013 Mar; 19(5):1269-80. doi:
10.1158/1078-0432.ccr-12-1092. [PMID: 23300276] - Shixiong Wang, Junjie Zhang, Xin Ye. [Protein kinase inhibitor flavopiridol inhibits the replication of influenza virus in vitro].
Wei sheng wu xue bao = Acta microbiologica Sinica.
2012 Sep; 52(9):1137-42. doi:
NULL. [PMID: 23236848] - Bhuvaneswari Ramaswamy, Mitch A Phelps, Robert Baiocchi, Tanios Bekaii-Saab, Wenjun Ni, Ju-Ping Lai, Anna Wolfson, Mark E Lustberg, Lai Wei, Deidre Wilkins, Angela Campbell, Daria Arbogast, Austin Doyle, John C Byrd, Michael R Grever, Manisha H Shah. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
Investigational new drugs.
2012 Apr; 30(2):629-38. doi:
10.1007/s10637-010-9563-7. [PMID: 20938713] - Liat Josefsberg Ben-Yehoshua, Katia Beider, Avichai Shimoni, Olga Ostrovsky, Michal Samookh, Amnon Peled, Arnon Nagler. Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death.
PloS one.
2012; 7(4):e33856. doi:
10.1371/journal.pone.0033856. [PMID: 22558078] - Murhaf Zaher, Massoud Mirshahi, Yusuf Nuraliev, Mijgana Sharifova, Isabelle Bombarda, Jean-Pierre Marie, Christian Billard. The BH3-only protein Noxa is stimulated during apoptosis of chronic lymphocytic leukemia cells triggered by M2YN, a new plant-derived extract.
International journal of oncology.
2011 Oct; 39(4):965-72. doi:
10.3892/ijo.2011.1121. [PMID: 21750864] - Mark Andrew Dickson, Dana E Rathkopf, Richard D Carvajal, Steven Grant, John D Roberts, Joel M Reid, Matthew M Ames, Renee M McGovern, Robert A Lefkowitz, Mithat Gonen, Lauren M Cane, Heather J Dials, Gary K Schwartz. A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.
Investigational new drugs.
2011 Oct; 29(5):1004-12. doi:
10.1007/s10637-010-9447-x. [PMID: 20461440] - Judith E Karp, B Douglas Smith, Linda S Resar, Jacqueline M Greer, Amanda Blackford, Ming Zhao, Dwella Moton-Nelson, Katrina Alino, Mark J Levis, Steven D Gore, Biju Joseph, Hetty Carraway, Michael A McDevitt, Lorena Bagain, Karen Mackey, Janet Briel, L Austin Doyle, John J Wright, Michelle A Rudek. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.
Blood.
2011 Mar; 117(12):3302-10. doi:
10.1182/blood-2010-09-310862. [PMID: 21239698] - Yue Song, Keng Shen, Feng Xu. [Synergism of antitumor effects on ovarian carcinoma using autocatalytic caspase-3 combined with flavopiridol].
Zhonghua fu chan ke za zhi.
2010 Oct; 45(10):781-6. doi:
. [PMID: 21176562] - Hiroshi Kodaira, Hiroyuki Kusuhara, Junko Ushiki, Eiichi Fuse, Yuichi Sugiyama. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
The Journal of pharmacology and experimental therapeutics.
2010 Jun; 333(3):788-96. doi:
10.1124/jpet.109.162321. [PMID: 20304939] - Patel Mohanakumara, Nambiar Sreejayan, Vaidayanathan Priti, Bheemanahally Thimmappa Ramesha, Gudasalamani Ravikanth, Kotiganahalli Narayanagowda Ganeshaiah, Ramesh Vasudeva, John Mohan, Thankayyan Retnabai Santhoshkumar, Prabhu Dutt Mishra, Viswakarma Ram, Ramanan Uma Shaanker. Dysoxylum binectariferum Hook.f (Meliaceae), a rich source of rohitukine.
Fitoterapia.
2010 Mar; 81(2):145-8. doi:
10.1016/j.fitote.2009.08.010. [PMID: 19686817] - Daniel Myatt, Louise Johnson, Sonja Baumli, Giuliano Siligardi. The binding of flavopiridol to blood serum albumin.
Chirality.
2010; 22 Suppl 1(?):E40-3. doi:
10.1002/chir.20925. [PMID: 21038395] - Lin Zhou, Kari Schmidt, Frederick R Nelson, Veronica Zelesky, Matthew D Troutman, Bo Feng. The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice.
Drug metabolism and disposition: the biological fate of chemicals.
2009 May; 37(5):946-55. doi:
10.1124/dmd.108.024489. [PMID: 19225039] - Mitch A Phelps, Thomas S Lin, Amy J Johnson, Eunju Hurh, Darlene M Rozewski, Katherine L Farley, Di Wu, Kristie A Blum, Beth Fischer, Sarah M Mitchell, Mollie E Moran, Michelle Brooker-McEldowney, Nyla A Heerema, David Jarjoura, Larry J Schaaf, John C Byrd, Michael R Grever, James T Dalton. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
Blood.
2009 Mar; 113(12):2637-45. doi:
10.1182/blood-2008-07-168583. [PMID: 18981292] - Xiaojuan Yang, Xiaobin Zhao, Mitch A Phelps, Longzhu Piao, Darlene M Rozewski, Qing Liu, L James Lee, Guido Marcucci, Michael R Grever, John C Byrd, James T Dalton, Robert J Lee. A novel liposomal formulation of flavopiridol.
International journal of pharmaceutics.
2009 Jan; 365(1-2):170-4. doi:
10.1016/j.ijpharm.2008.08.008. [PMID: 18778761] - Beth A Christian, Michael R Grever, John C Byrd, Thomas S Lin. Flavopiridol in chronic lymphocytic leukemia: a concise review.
Clinical lymphoma & myeloma.
2009; 9 Suppl 3(?):S179-85. doi:
10.3816/clm.2009.s.009. [PMID: 19778838] - Qing Liu, Katherine L Farley, Amy J Johnson, Natarajan Muthusamy, Craig C Hofmeister, Kristie A Blum, Larry J Schaaf, Michael R Grever, John C Byrd, James T Dalton, Mitch A Phelps. Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.
Therapeutic drug monitoring.
2008 Oct; 30(5):620-7. doi:
10.1097/ftd.0b013e318185813d. [PMID: 18708993] - Mitch A Phelps, Darlene M Rozewski, Jeffrey S Johnston, Katherine L Farley, Katie A Albanese, John C Byrd, Thomas S Lin, Michael R Grever, James T Dalton. Development and validation of a sensitive liquid chromatography/mass spectrometry method for quantitation of flavopiridol in plasma enables accurate estimation of pharmacokinetic parameters with a clinically active dosing schedule.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2008 Jun; 868(1-2):110-5. doi:
10.1016/j.jchromb.2008.04.023. [PMID: 18490204] - Chiyoko Sekine, Takahiko Sugihara, Sachiko Miyake, Hiroshi Hirai, Mitsuaki Yoshida, Nobuyuki Miyasaka, Hitoshi Kohsaka. Successful treatment of animal models of rheumatoid arthritis with small-molecule cyclin-dependent kinase inhibitors.
Journal of immunology (Baltimore, Md. : 1950).
2008 Feb; 180(3):1954-61. doi:
10.4049/jimmunol.180.3.1954. [PMID: 18209094] - Beth A Christian, Michael R Grever, John C Byrd, Thomas S Lin. Flavopiridol in the treatment of chronic lymphocytic leukemia.
Current opinion in oncology.
2007 Nov; 19(6):573-8. doi:
10.1097/cco.0b013e3282efb9da. [PMID: 17906454] - Alex H Beesley, Misty-Lee Palmer, Jette Ford, Renae E Weller, Aaron J Cummings, Joseph R Freitas, Martin J Firth, Kanchana U Perera, Nicholas H de Klerk, Ursula R Kees. In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia.
British journal of haematology.
2007 Apr; 137(2):109-16. doi:
10.1111/j.1365-2141.2007.06527.x. [PMID: 17391490] - James A Whitlock, Mark Krailo, Joel M Reid, Stacie L Ruben, Matthew M Ames, William Owen, Gregory Reaman. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2005 Dec; 23(36):9179-86. doi:
10.1200/jco.2004.01.0660. [PMID: 16361620] - Daniel W Nelson, Hongbin Cao, Yonghua Zhu, Bulbin Sunar-Reeder, Clara Y H Choi, James D Faix, J Martin Brown, Albert C Koong, Amato J Giaccia, Quynh-Thu Le. A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia.
Cancer research.
2005 Jul; 65(14):6151-8. doi:
10.1158/0008-5472.can-04-2602. [PMID: 16024616] - Peter J Van Veldhuizen, James R Faulkner, Primo N Lara, Paul H Gumerlock, J Wendall Goodwin, Shaker R Dakhil, Howard M Gross, Robert C Flanigan, E David Crawford. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
Cancer chemotherapy and pharmacology.
2005 Jul; 56(1):39-45. doi:
10.1007/s00280-004-0969-9. [PMID: 15791454] - Frank Mayer, Sandra Mueller, Elke Malenke, M Kuczyk, Jörg T Hartmann, Carsten Bokemeyer. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines.
Investigational new drugs.
2005 Jun; 23(3):205-11. doi:
10.1007/s10637-005-6728-x. [PMID: 15868376] - Manish A Shah, Jeremy Kortmansky, Monica Motwani, Marija Drobnjak, Mithat Gonen, Sandy Yi, Amanda Weyerbacher, Carlos Cordon-Cardo, Robert Lefkowitz, Baruch Brenner, Eileen O'Reilly, Leonard Saltz, William Tong, David P Kelsen, Gary K Schwartz. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2005 May; 11(10):3836-45. doi:
10.1158/1078-0432.ccr-04-2651. [PMID: 15897584] - Meili Zhang, Zhuo Zhang, Carolyn K Goldman, John Janik, Thomas A Waldmann. Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody.
Blood.
2005 Feb; 105(3):1231-6. doi:
10.1182/blood-2004-05-1709. [PMID: 15383455] - Ester Verdaguer, Elvira G Jordà, Daniel Alvira, Andrés Jiménez, Anna Maria Canudas, Jaume Folch, Victor Rimbau, Mercè Pallàs, Antoni Camins. Inhibition of multiple pathways accounts for the antiapoptotic effects of flavopiridol on potassium withdrawal-induced apoptosis in neurons.
Journal of molecular neuroscience : MN.
2005; 26(1):71-84. doi:
10.1385/jmn:26:1:071. [PMID: 15968087] - Adrian M Senderowicz. Inhibitors of cyclin-dependent kinase modulators for cancer therapy.
Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
2005; 63(?):183-206. doi:
10.1007/3-7643-7414-4_8. [PMID: 16265881] - Yasunari Takada, Bharat B Aggarwal. Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9.
The Journal of biological chemistry.
2004 Feb; 279(6):4750-9. doi:
10.1074/jbc.m304546200. [PMID: 14630924] - W Jäger, E Gehring, B Hagenauer, S Aust, A Senderowicz, T Thalhammer. Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2).
Life sciences.
2003 Oct; 73(22):2841-54. doi:
10.1016/s0024-3205(03)00699-4. [PMID: 14511769] - Michelle A Rudek, Kenneth S Bauer, Richard M Lush, Sherman F Stinson, Adrian M Senderowicz, Donna J Headlee, Susan G Arbuck, Michael C Cox, Anthony J Murgo, Edward A Sausville, William D Figg. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
The Annals of pharmacotherapy.
2003 Oct; 37(10):1369-74. doi:
10.1345/aph.1c404. [PMID: 14519054] - Adrian M Senderowicz. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Cancer chemotherapy and pharmacology.
2003 Jul; 52 Suppl 1(?):S61-73. doi:
10.1007/s00280-003-0624-x. [PMID: 12819936] - Peter J Nelson, Vivette D D'Agati, Jean-Michel Gries, Jose-Ramon Suarez, Irwin H Gelman. Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol.
The Journal of antimicrobial chemotherapy.
2003 Apr; 51(4):921-9. doi:
10.1093/jac/dkg175. [PMID: 12654740] - Richard A Messmann, Claudio Dansky Ullmann, Tyler Lahusen, Audrey Kalehua, Jason Wasfy, Giovanni Melillo, Ivan Ding, Donna Headlee, William D Figg, Edward A Sausville, Adrian M Senderowicz. Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2003 Feb; 9(2):562-70. doi:
NULL. [PMID: 12576419] - James P Thomas, Kendra D Tutsch, James F Cleary, Howard H Bailey, Rhoda Arzoomanian, Dona Alberti, Kris Simon, Chris Feierabend, Kimberly Binger, Rebecca Marnocha, Amy Dresen, George Wilding. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
Cancer chemotherapy and pharmacology.
2002 Dec; 50(6):465-72. doi:
10.1007/s00280-002-0527-2. [PMID: 12451473] - Chuenlei Parng, Wen Lin Seng, Carlos Semino, Patricia McGrath. Zebrafish: a preclinical model for drug screening.
Assay and drug development technologies.
2002 Nov; 1(1 Pt 1):41-8. doi:
10.1089/154065802761001293. [PMID: 15090155] - Ivana Gojo, Bin Zhang, Robert G Fenton. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2002 Nov; 8(11):3527-38. doi:
NULL. [PMID: 12429644] - Adrian M Senderowicz. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
Hematology/oncology clinics of North America.
2002 Oct; 16(5):1229-53. doi:
10.1016/s0889-8588(02)00049-7. [PMID: 12512390] - Antoinette R Tan, Donna Headlee, Richard Messmann, Edward A Sausville, Susan G Arbuck, Anthony J Murgo, Giovanni Melillo, Suoping Zhai, William D Figg, Sandra M Swain, Adrian M Senderowicz. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2002 Oct; 20(19):4074-82. doi:
10.1200/jco.2002.01.043. [PMID: 12351605] - Suoping Zhai, Edward Sausville, William D Figg. A high-performance liquid chromatography method using ultraviolet detection for the quantitation of flavopiridol from human plasma.
Biomedical chromatography : BMC.
2002 Sep; 16(6):379-82. doi:
10.1002/bmc.166. [PMID: 12228893] - Suoping Zhai, Adrian M Senderowicz, Edward A Sausville, William D Figg. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
The Annals of pharmacotherapy.
2002 May; 36(5):905-11. doi:
10.1345/aph.1a162. [PMID: 11978170] - Jacqueline Ramírez, Lalitha Iyer, Kim Journault, Patrick Bélanger, Federico Innocenti, Mark J Ratain, Chantal Guillemette. In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes.
Pharmaceutical research.
2002 May; 19(5):588-94. doi:
10.1023/a:1015341726183. [PMID: 12069159] - Thomas S Lin, Orion M Howard, Donna S Neuberg, Helen H Kim, Margaret A Shipp. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma.
Leukemia & lymphoma.
2002 Apr; 43(4):793-7. doi:
10.1080/10428190290016908. [PMID: 12153166] - Peter J Nelson, Irwin H Gelman, Paul E Klotman. Suppression of HIV-1 expression by inhibitors of cyclin-dependent kinases promotes differentiation of infected podocytes.
Journal of the American Society of Nephrology : JASN.
2001 Dec; 12(12):2827-2831. doi:
10.1681/asn.v12122827. [PMID: 11729253] - N Pathan, C Aime-Sempe, S Kitada, A Basu, S Haldar, J C Reed. Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pin1.
Neoplasia (New York, N.Y.).
2001 Nov; 3(6):550-9. doi:
10.1038/sj.neo.7900213. [PMID: 11774038] - G I Shapiro, J G Supko, A Patterson, C Lynch, J Lucca, P F Zacarola, A Muzikansky, J J Wright, T J Lynch, B J Rollins. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2001 Jun; 7(6):1590-9. doi:
NULL. [PMID: 11410495] - T Bachrich, T Thalhammer, W Jäger, P Haslmayer, B Alihodzic, S Bakos, E Hitchman, A M Senderowicz, E Penner. Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases.
Hepatology (Baltimore, Md.).
2001 May; 33(5):1053-9. doi:
10.1053/jhep.2001.24101. [PMID: 11343231] - G K Schwartz, D Ilson, L Saltz, E O'Reilly, W Tong, P Maslak, J Werner, P Perkins, M Stoltz, D Kelsen. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2001 Apr; 19(7):1985-92. doi:
10.1200/jco.2001.19.7.1985. [PMID: 11283131] - S Leclerc, M Garnier, R Hoessel, D Marko, J A Bibb, G L Snyder, P Greengard, J Biernat, Y Z Wu, E M Mandelkow, G Eisenbrand, L Meijer. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?.
The Journal of biological chemistry.
2001 Jan; 276(1):251-60. doi:
10.1074/jbc.m002466200. [PMID: 11013232] - A M Senderowicz. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
Leukemia.
2001 Jan; 15(1):1-9. doi:
10.1038/sj.leu.2401994. [PMID: 11243375] - L R Kelland. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status.
Expert opinion on investigational drugs.
2000 Dec; 9(12):2903-11. doi:
10.1517/13543784.9.12.2903. [PMID: 11093360] - F Innocenti, W M Stadler, L Iyer, J Ramírez, E E Vokes, M J Ratain. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2000 Sep; 6(9):3400-5. doi:
NULL. [PMID: 10999721] - A M Senderowicz, E A Sausville. Preclinical and clinical development of cyclin-dependent kinase modulators.
Journal of the National Cancer Institute.
2000 Mar; 92(5):376-87. doi:
10.1093/jnci/92.5.376. [PMID: 10699068] - W M Stadler, N J Vogelzang, R Amato, J Sosman, D Taber, D Liebowitz, E E Vokes. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2000 Jan; 18(2):371-5. doi:
10.1200/jco.2000.18.2.371. [PMID: 10637252] - K Lu, C Shih, B A Teicher. Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents.
Cancer chemotherapy and pharmacology.
2000; 46(4):293-304. doi:
10.1007/s002800000136. [PMID: 11052627] - J H Hooijberg, H J Broxterman, G L Scheffer, C Vrasdonk, M Heijn, M C de Jong, R J Scheper, J Lankelma, H M Pinedo. Potent interaction of flavopiridol with MRP1.
British journal of cancer.
1999 Sep; 81(2):269-76. doi:
10.1038/sj.bjc.6690687. [PMID: 10496352] - A M Senderowicz. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
Investigational new drugs.
1999; 17(3):313-20. doi:
10.1023/a:1006353008903. [PMID: 10665481] - A M Senderowicz, D Headlee, S F Stinson, R M Lush, N Kalil, L Villalba, K Hill, S M Steinberg, W D Figg, A Tompkins, S G Arbuck, E A Sausville. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
1998 Sep; 16(9):2986-99. doi:
10.1200/jco.1998.16.9.2986. [PMID: 9738567] - F Fogt, A O Vortmeyer, A M Senderowicz. Sodium polystyrene sulfonate damage.
The American journal of surgical pathology.
1998 Mar; 22(3):379-80. doi:
10.1097/00000478-199803000-00016. [PMID: 9500782] - S F Stinson, K Hill, T J Siford, L R Phillips, T W Daw. Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection.
Cancer chemotherapy and pharmacology.
1998; 42(4):261-5. doi:
10.1007/s002800050815. [PMID: 9744769] - J H Hooijberg, H J Broxterman, M Heijn, D L Fles, J Lankelma, H M Pinedo. Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein.
FEBS letters.
1997 Aug; 413(2):344-8. doi:
10.1016/s0014-5793(97)00940-x. [PMID: 9280310] - D S Park, S E Farinelli, L A Greene. Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons.
The Journal of biological chemistry.
1996 Apr; 271(14):8161-9. doi:
10.1074/jbc.271.14.8161. [PMID: 8626506]